Skip to main content

Yolanda Villena Ortiz

Institutions of which they are part

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca
Yolanda Villena Ortiz

Yolanda Villena Ortiz

Yolanda Villena Ortiz

Institutions of which they are part

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Projects

Estudio de validación de una aplicación para Smartphone (NORA) en pacientes con enfermedad renal diabética avanzada. Efecto en la progresión de la enfermedad renal y la mortalidad cardiovascular en época COVID.

IP: Maria Jose Soler Romeo
Collaborators: Yolanda Villena Ortiz, Joan López Hellin
Funding agency: Sociedad Española de Nefrología (S.E.N.)
Funding: 24000
Reference: SENEFRO/PROJECTES/2021/SOLER
Duration: 15/07/2021 - 14/01/2023

Related news

The annual event offered a space for dialogue between the scientific community and society on how to address the future of ageing through research and innovation.

Docetaxel, carried by Soluplus, proved to be the most effective and least toxic combination to cross the blood-brain barrier and attack the tumour directly.

Based on the study led by VHIR, a clinical trial has been approved for patients with locally advanced pancreatic cancer.

Related professionals

Susana Miravet Delgado

Susana Miravet Delgado

Postdoctoral researcher
Gene Therapy at Nervous System
Read more
Carlos Torrico Leon

Carlos Torrico Leon

Research technician
Donation and transplantation of organs, tissues and cells
Read more
Elsa Ibarrola Carrasco

Elsa Ibarrola Carrasco

Research technician
Gene Therapy at Nervous System
Read more
M.Luisa Perez Rodriguez

M.Luisa Perez Rodriguez

Postdoctoral researcher
Donation and transplantation of organs, tissues and cells
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.